Buscar
Mostrando ítems 1-5 de 5
Artículo
Efficacy of β-lactam/β-lactamase inhibitors to treat extended-spectrum beta-lactamase-producing Enterobacterales bacteremia secondary to urinary tract infection in kidney transplant recipients
(Willey-Blackwell, 2021)
Background Whether active therapy with β-lactam/β-lactamase inhibitors (BLBLI) is as affective as carbapenems for extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E) bloodstream infection (BSI) secondary ...
Artículo
Intestinal colonization due to Escherichia coli ST131: Risk factors and prevalence
(Biomed Central, 2018-11-15)
Background Escherichia coli sequence type 131 (ST131) is a successful clonal group that has dramatically spread during the last decades and is considered an important driver for the rapid increase of quinolone resistance ...
Artículo
CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant enterobacterales
(2021-02-24)
Carbapenems are considered the drugs of choice for the treatment of serious infections caused by ceftriaxone resistant Enterobacterales. However, because of the dramatic increase in carbapenem-resistant organisms worldwide, ...
Artículo
Propensity score and desirability of outcome ranking analysis of ertapenem for treatment of nonsevere bacteremic urinary tract infections due to extended-spectrum-beta-lactamase-producing enterobacterales in kidney transplant recipients
(American Society Microbiology, 2021)
There are scarce data on the efficacy of ertapenem in the treatment of bacteremia due to extended-spectrum-beta-lactamase (ESBL)-producing Enterobacterales (ESBL-E) in kidney transplant (KT) recipients. We evaluated the ...
Artículo
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
(BMJ Publishing Group, 2021)
Introduction: Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E). Temocillin is a suitable candidate, but comparative randomised studies are lacking. ...